Moreover, in our studies, normal mononuclear cells were significantly less inhibited by dual PI3K/MTOR inhibition than leukemia cells, indicating a therapeutic gap of these agents in the treatment of acute leukemia without significant suppression of normal hematopoiesis. Here, PIK3CA is linked to leukemia.